Clinical Trial Update: Real World Use of Emicizumab in Infants and Children Ages 0-3 Years With Hemophilia A

View source ↗

Summary

A completed observational study evaluating real-world use of emicizumab in infants and young children aged 0-3 years with Hemophilia A, reporting safety and eff…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• Emicizumab (emicizumab)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Hemophilia A | Status: COMPLETED